nCoV: Rapid Clinical Development of ChAdOx1 nCoV-19

  • Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Total publications:35 publications

Grant number: MC_PC_19055

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $2,788,155.14
  • Funder

    Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Principle Investigator

    Pending
  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    University of Oxford
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

This COVID-19 Rapid Response award is jointly funded (50:50) between the Medical Research Council and the National Institute for Health Research. The figure displayed is the total award amount of the two funders combined, with each partner contributing equally towards the project. ChAdOx1 is a replication-deficient simian adenoviral vector that provides a platform technology for the production of vaccines against many infectious diseases. For Middle East Respiratory Syndrome (MERS) coronavirus, a single dose of the ChAdOx1-vectored MERS vaccine resulted in protection against MERS challenge in non-human primates and the induction of strong humoral and T cell responses in a Phase I clinical trial. The same vaccine design has now been followed to produce ChAdOx1 nCoV. Preclinical studies of the vaccine will be initiated by the end of February. This will include demonstration of vaccine immunogenicity (antibody and T cell) in mice, followed by vaccine immunogenicity and efficacy against nCoV-19 challenge in ferrets and non-human primates with collaborators at PHE Porton Down and NIH. A pre-GMP vaccine seed stock is in production at Oxford's GMP manufacturing facility, and will be provided to Advent, Italy, which will produce the first 1000 doses for clinical studies. In parallel with preclinical studies and vaccine manufacturing, Oxford will work with the MHRA on a rapid release testing package. This will employ deep sequencing of the Cell Harvest and Drug Substance to identify any potential replication competent adenovirus and adventitious agents rather than following the existing set of in vivo and in vitro assays, greatly reducing the time to cGMP certification. A phase I/II clinical trial will then be undertaken to demonstrate vaccine safety and immunogenicity in adults, older adults and children.

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.